Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Satisfaction study of split-dose Bocouture with double treatment frequency
2025-520915-14-00Phase 3Completed
- Sponsor
- Falck
- Start
- Jan 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of botulinum toxin type A in rhytides and fine lines (2 arms), sponsored by Falck. Primary endpoint: Change from baseline in eVAS Overall Satisfaction Score at Visit 6. Started Jan 2023; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
rhytidesfine lines
Beyond the preview
Go deeper on 2025-520915-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520915-14-00.